EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI

Objective: to study the efficiency of combination therapy with Amelotex®and Compligam B®in patients with osteoarthrosis with the signs of knee joint synovitis. Subjects and methods. The efficiency of combination therapy with Amelotex®and Compligam B®was studied in 40 patients. During a Phase I trial...

Full description

Bibliographic Details
Main Authors: O N Bakhareva, A V Solovyeva, Lesya Vasilyevna Chichanovskaya, V M Bryantseva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2010-06-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/289
_version_ 1797876842212884480
author O N Bakhareva
A V Solovyeva
Lesya Vasilyevna Chichanovskaya
V M Bryantseva
author_facet O N Bakhareva
A V Solovyeva
Lesya Vasilyevna Chichanovskaya
V M Bryantseva
author_sort O N Bakhareva
collection DOAJ
description Objective: to study the efficiency of combination therapy with Amelotex®and Compligam B®in patients with osteoarthrosis with the signs of knee joint synovitis. Subjects and methods. The efficiency of combination therapy with Amelotex®and Compligam B®was studied in 40 patients. During a Phase I trial, Amelotex®was administered in a dose of 1,5 ml (15 mg) as periarticular blocks, by alternating intramuscular Compligam B®in a dose of 2,0 ml. In a Phase II trial, the intramuscular injection of these drugs was alternated. Electroneuromyography (ENMG) was performed and the levels of proinflammatory cytokine interleukin-1β (IL-1β) and IL-8 were determined over time (before and on 10 and 20 days of therapy). Quality of life was assessed by a 100-mm visual analog scale before and after therapy. Results. The early sign of therapeutic efficiency was a significant reduction in the magnitude of knee joint pain, which was observed just after completion of the Phase I trial. Diminished limb cacesthesia and crepitation were most important after the end of Phase II. Synovitis cases significantly reduced in number. Recovered peripheral nerve function was objectively supported by an increase in ENMG parameters, such as the amplitude of M responses in the peroneal nerve and sensor fiber action potential in the sural nerve. After termination of the therapy, IL-1β levels became significantly lower. Quality of life improved, as shown by VAS scores. Conclusion. The findings suggest that combination therapy with Amelotex® and Compligam B® shows clinical effectivene
first_indexed 2024-04-10T02:08:55Z
format Article
id doaj.art-9d6abe278e64450ba2099a2c02996fec
institution Directory Open Access Journal
issn 1996-7012
2310-158X
language Russian
last_indexed 2024-04-10T02:08:55Z
publishDate 2010-06-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj.art-9d6abe278e64450ba2099a2c02996fec2023-03-13T08:39:21ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2010-06-0142586210.14412/1996-7012-2010-6041594EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSIO N BakharevaA V SolovyevaLesya Vasilyevna ChichanovskayaV M BryantsevaObjective: to study the efficiency of combination therapy with Amelotex®and Compligam B®in patients with osteoarthrosis with the signs of knee joint synovitis. Subjects and methods. The efficiency of combination therapy with Amelotex®and Compligam B®was studied in 40 patients. During a Phase I trial, Amelotex®was administered in a dose of 1,5 ml (15 mg) as periarticular blocks, by alternating intramuscular Compligam B®in a dose of 2,0 ml. In a Phase II trial, the intramuscular injection of these drugs was alternated. Electroneuromyography (ENMG) was performed and the levels of proinflammatory cytokine interleukin-1β (IL-1β) and IL-8 were determined over time (before and on 10 and 20 days of therapy). Quality of life was assessed by a 100-mm visual analog scale before and after therapy. Results. The early sign of therapeutic efficiency was a significant reduction in the magnitude of knee joint pain, which was observed just after completion of the Phase I trial. Diminished limb cacesthesia and crepitation were most important after the end of Phase II. Synovitis cases significantly reduced in number. Recovered peripheral nerve function was objectively supported by an increase in ENMG parameters, such as the amplitude of M responses in the peroneal nerve and sensor fiber action potential in the sural nerve. After termination of the therapy, IL-1β levels became significantly lower. Quality of life improved, as shown by VAS scores. Conclusion. The findings suggest that combination therapy with Amelotex® and Compligam B® shows clinical effectivenehttps://mrj.ima-press.net/mrj/article/view/289амелотекскомплигам востеоартрозлечение
spellingShingle O N Bakhareva
A V Solovyeva
Lesya Vasilyevna Chichanovskaya
V M Bryantseva
EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI
Современная ревматология
амелотекс
комплигам в
остеоартроз
лечение
title EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI
title_full EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI
title_fullStr EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI
title_full_unstemmed EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI
title_short EXPERIENCE WITH COMBINATION THERAPY WITH AMELOTEX®AND COMPLIGAM B®IN PATIENTS WITH MANIFESTATIONS OF SYNOVITIS IN THE PRESENCE OF KNEE OSTEOARTHROSI
title_sort experience with combination therapy with amelotex r and compligam b r in patients with manifestations of synovitis in the presence of knee osteoarthrosi
topic амелотекс
комплигам в
остеоартроз
лечение
url https://mrj.ima-press.net/mrj/article/view/289
work_keys_str_mv AT onbakhareva experiencewithcombinationtherapywithamelotexandcompligambinpatientswithmanifestationsofsynovitisinthepresenceofkneeosteoarthrosi
AT avsolovyeva experiencewithcombinationtherapywithamelotexandcompligambinpatientswithmanifestationsofsynovitisinthepresenceofkneeosteoarthrosi
AT lesyavasilyevnachichanovskaya experiencewithcombinationtherapywithamelotexandcompligambinpatientswithmanifestationsofsynovitisinthepresenceofkneeosteoarthrosi
AT vmbryantseva experiencewithcombinationtherapywithamelotexandcompligambinpatientswithmanifestationsofsynovitisinthepresenceofkneeosteoarthrosi